Citigroup Inc Tiziana Life Sciences LTD Call Options Transaction History
Citigroup Inc
- $169 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TLSA
# of Institutions
31Shares Held
1.03MCall Options Held
19.2KPut Options Held
0-
Geode Capital Management, LLC Boston, MA219KShares$194,6260.0% of portfolio
-
Hsbc Holdings PLC London, X0115KShares$102,6740.0% of portfolio
-
Morgan Stanley New York, NY110KShares$97,6740.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il104KShares$92,8180.0% of portfolio
-
Kovitz Investment Group Partners, LLC79.4KShares$70,6340.0% of portfolio
About Tiziana Life Sciences Ltd
- Ticker TLSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,273,000
- Market Cap $91M
- Description
- Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...